Metraipolis › archive › dc_3dbca8fceaa7

Early Evaluation of the Food and Drug Administration (FDA) Adverse Event Monitoring System (AEMS): An Analysis of Over 32 Million Pharmacovigilance Reports — Europe PMC PMID:42078215

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42078215
DOI
10.7759/cureus.106259
License (as archived)
solo-consultazione
Archived
2026-11-03T13:18:27.432Z
SHA-256 of the archived text
c579b9789849b9569e592b5b4bbcf4ac347f6be4899bedd7503e0301e9427d92
Stable URL of this page
https://metraipolis.com/documento/dc_3dbca8fceaa7

How to cite

Early Evaluation of the Food and Drug Administration (FDA) Adverse Event Monitoring System (AEMS): An Analysis of Over 32 Million Pharmacovigilance Reports — Europe PMC PMID:42078215 — Europe PMC (en), https://europepmc.org/article/MED/42078215 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_3dbca8fceaa7 (Metraipolis archive dc_3dbca8fceaa7, sha256 c579b9789849b9569e592b5b4bbcf4ac347f6be4899bedd7503e0301e9427d92)
BibTeX
@misc{dc3dbca8fceaa7,
  title = {Early Evaluation of the Food and Drug Administration (FDA) Adverse Event Monitoring System (AEMS): An Analysis of Over 32 Million Pharmacovigilance Reports — Europe PMC PMID:42078215},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42078215},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_3dbca8fceaa7; sha256 c579b9789849b9569e592b5b4bbcf4ac347f6be4899bedd7503e0301e9427d92},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42078215. Agents can read the archived copy with the MCP tool read_document.